Sage Journals: Discover world-class research

Abstract

Background: Several studies suggest that inhaled and oral corticosteroids repress systemic inflammation in chronic obstructive pulmonary disease (COPD). However, the cytokines that may respond to these medications are unclear.

Method: We used data from 41 patients with a history of stable moderate COPD (average age 64 years) who were randomised to inhaled fluticasone (500 μg twice daily from a Diskus inhaler), oral prednisone (30 mg daily) or placebo for 2 weeks. Using a multiplexed array system, different serum cytokines that have been implicated in COPD pathogenesis were measured.

Results: We found that compared with placebo, inhaled fluticasone significantly reduced levels of soluble tumour necrosis factor receptor-2 (sTNF-R2) by 24% (95% CI, 7—38%; p = 0.01), monocyte chemoattractant protein-1 by 20% (95% CI, 5—32%; p = 0.01), interferon gamma inducible CXCL10 (IP-10) by 43% (95% CI, 3—66%; p = 0.04), and soluble L-selectin levels by 15% (95% CI, 1—28%; p = 0.04). Compared with placebo, oral prednisone reduced levels of sTNF-R2 by 26% (95% CI, 15—36%; p < 0.001), L-selectin by 22% (95% CI, 8—34%; p = 0.004), intercellular adhesion molecule-1 by 31% (95% CI, 9—48%; p = 0.01), pulmonary and activation-regulated chemokine (PARC) by 18% (95% CI, 2—32%; p = 0.03) and IP-10 by 40% (95% CI, 0—64%; p = 0.05). sTNF-R2, L-selectin and IP-10 were significantly reduced by both oral and inhaled corticosteroids. The other cytokines were not significantly repressed by either oral or inhaled corticosteroids.

Conclusions: In summary, inhaled and oral corticosteroids significantly repressed a selected number of systemic cytokines in patients with stable, moderate COPD; most of the steroid-responsive cytokines appear to be chemoattractants.

Keywords

Biomarker COPD corticosteroids fluticasone prednisone

References

Barnes, N.C. , Qiu, Y.S. , Pavord, I.D. , Parker, D. , Davis, P.A. , Zhu, J. et al. (2006). Anti inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173: 736-743.

Barnes, P.J. , Shapiro, S.D. and Pauwels, R.A. (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22: 672-688.

Bender, R. and Lange, S. (2001). Adjusting for multiple testing - when and how ? J Clin Epidemiol 54: 343-349.

Blankenberg, S. , Barbaux, S. and Tiret, L. (2003). Adhesion molecules and atherosclerosis. Atherosclerosis 170: 191-203.

Burge, P.S. , Calverley, P.M. , Jones, P.W. , Spencer, S. , Anderson, J.A. and Maslen, T.K. (2000). Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320: 1297-1303.

Gan, W.Q. , Man, S.F. , Senthilselvan, A. and Sin, D.D. (2004). Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis . Thorax 59: 574-580.

Huiart, L. , Ernst, P. , Ranouil, X. and Suissa, S. (2005). Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 25: 634-639.

Jemal, A. , Ward, E. , Hao, Y. and Thun, M. (2005). Trends in the leading causes of death in the United States, 1970-2002. J Am Med Assoc 294: 1255-1259.

Kadioglu, A. and Sheldon, P. (1998). Steroid pulse therapy for rheumatoid arthritis: effect on lymphocyte subsets and mononuclear cell adhesion. Br J Rheumatol 37: 282-286.

10.

Keh, D. , Boehnke, T. , Weber-Cartens, S. , Schulz, C. , Ahlers, O. , Bercker, S. et al. (2003). Immunologic and hemodynamic effects of `low-dose' hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167: 512-520.

11.

Lofdahl, C.G. , Postma, D.S. , Pride, N.B. , Boe, J. and Thoren, A. (2007). Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 29: 1115-1119.

12.

Macie, C. , Wooldrage, K. , Manfreda, J. and Anthonisen, N.R. (2006). Inhaled corticosteroids and mortality in COPD. Chest 130: 640-646.

13.

Ohta, K. and Yamashita, N. (1999). Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 104: 14-21.

14.

Pai, J.K. , Pischon, T. , Ma, J. , Manson, J.E. , Hankinson, S.E. , Joshipura, K. et al. (2004). Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610.

15.

Parimon, T. , Chien, J.W. , Bryson, C.L. , McDonell, M.B. , Udris, E.M. and Au, D.H. (2007). Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 712-719.

16.

Pauwels, R.A. and Rabe, K.F. (2004). Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364: 613-620.

17.

Pinto-Plata, V. , Toso, J. , Lee, K. , Park, D. , Bilello, J. , Mullerova, H. et al. (2007). Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 62: 595-601.

18.

Schuld, A. , Kraus, T. , Haack, M. , Hinze-Selch, D. , Zobel, A.W. , Holsboer, F. et al. (2001). Effects of dexamethasone on cytokine plasma levels and white blood cell counts in depressed patients. Psychoneuroendocrinology 26: 65-76.

19.

Shai, I. , Schulze, M.B. , Manson, J.E. , Rexrode, K.M. , Stampfer, M.J. , Mantzoros, C. et al. (2005). A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 28: 1376-1382.

20.

Sin, D.D. , Lacy, P. , York, E. and Man, S.F. (2004). Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 760-765.

21.

Sin, D.D. and Man, S.F. (2003). Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107: 1514-1519.

22.

Stoeck, M. , Schafer, M. , Hofmann, H.P. and Gekeler, V. (2000). Dexamethasone and cyclosporin A do not inhibit interleukin-15 expression in the human lung carcinoma cell line A549. Eur Cytokine Netw 11: 414-419.

The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study

Abstract

Keywords

References